<DOC>
	<DOCNO>NCT02645032</DOCNO>
	<brief_summary>This Phase I , Randomized , observer-blinded , age de-escalating study . The study objective evaluate safety 25 μg Vi-DT typhoid conjugate vaccine administer 0 4 week . assess immunogenicity 25 μg Vi-DT typhoid conjugate vaccine administer 0 4 week . compare safety immunogenicity Vi-DT Vi-Polysaccharide typhoid vaccine .</brief_summary>
	<brief_title>Safety Immunogenicity Vi-DT Typhoid Conjugate Vaccine</brief_title>
	<detailed_description>This study carry healthy adult child single site . Subjects stratify accord age . The study procedure follow : Visit 1 ( day-1 -7 ) : Screen participant medical history , physical examination lab investigation . Collect blood safety immunogenicity assessment . Visit 2 ( day 0 ) : Enroll , randomize administer first dose vaccine eligible participant Visit 3 ( day 3 ) : Assess participant safety medical history physical examination Visit 4 ( day 7 ) : Record solicit adverse reaction 7 day post vaccination , collect blood safety lab assessment . Visit 5 ( day 28 ) : Assess participant safety , collect blood immunogenicity assessment , administer second vaccine dose Visit 6 ( day 31 ) : Participants safety assess medical history physical examination Visit 7 ( day 35 ) : Record solicit adverse reaction 7 day post second vaccination . Visit 8 ( day 56 ) : Collect blood immunogenicity assessment , ass participant safety , fill study completion form absence safety concern . This study observer-blind : vaccine administrator vaccine safety evaluator two distinct person avoid bias safety assessment . Trial staff vaccine administrator .</detailed_description>
	<mesh_term>Typhoid Fever</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Healthy male female individual 245 year age 2 . Participants/Parents voluntarily give informed consent and/or assent . 3 . Participants/Parents willing commit comply study procedure investigator available entire duration study 1 . Participants concomitantly enrol schedule enrol another trial 2 . Acute illness , particular infectious disease fever ( axillary temperature &gt; 38°C ) , three day prior enrollment vaccination . 3 . Known history allergy vaccine medication 4 . Known history allergy egg , chiken protein , neomycin formaldehyde . 5 . History uncontrolled coagulopathy blood disorder 6 . Known history immune function disorder include immunodeficiency disease , chronic use systemic steroid ( &gt; 20 mg/day prednisone equivalent period exceed 10 day ) , cytotoxic immunosuppressive drug 7 . Any abnormality chronic disease opinion investigator might detrimental safety participant interfere assessment trial objective 8 . Pregnancy &amp; Lactation ( female adult ) 9 . Female childbearing potential study period . i.e. , sexually active practice effective acceptable contraceptive method 10 . Individuals previously receive vaccine typhoid fever 11 . Individuals already immunize licensed vaccine within 4 week prior enrolment/vaccination ( day 0 ) expect receive license vaccine within 60 day follow first dose ( day 0 ) , except tetanus toxoid vaccine 12 . Individuals previously ascertain suspected disease cause S. typhi . 13 . Individuals household contact with/and intimate exposure individual laboratoryconfirmed S. typhi 14 . History alcohol substance abuse 15 . Subject plan move study area end study period</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Typhoid conjugate vaccine</keyword>
	<keyword>Vi-DT</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicuty</keyword>
</DOC>